Bioxcel Therapeutics (BTAI) sNDA Decision Coming (10% Long Shot)

$Bioxcel Therapeutics Inc.(BTAIQ)$  


BioXcel Therapeutics entered a super-priority senior secured priming debtor-in-possession credit agreement with Oaktree affiliates and Qatar Investment Authority affiliates.

BTAI (BioXcel Therapeutics): sNDA decision for Igalmi, PDUFA Nov 14. One tracker puts approval odds near 10%, so it's a long shot.

 

DIP facility totals up to $77.25 million, including up to $19 million of new money term loans.

Facility also includes up to $58.25 million of roll-up loans converting prepetition debt, including a $1.25 million bridge loan.

Borrowings carry a 13% interest rate; roll-up interest capitalizes; 4% exit fee payable on repayment or prepayment.

Matures Jan. 27, 2027; proceeds fund Chapter 11 working capital and case costs; lenders receive superpriority claims and priming liens.


Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment(2)

  • Top
  • Latest
  • WebbBart
    ·11-13
    Approval is a long shot, but if it clears can Igalmi actually commercialize normally through Chapter 11
    Reply
    Report
  • keke006
    ·11-13
    13% paper plus a 4% exit fee is brutal. With 0.09 quick ratio, this feels priced for survival, not equity upside
    Reply
    Report